Qi Lu Wan Bao·2026-02-28 12:11Core Viewpoint - The annual "Spring Research Symposium" of Shandong Xinhua Pharmaceutical Co., Ltd. reflects the company's commitment to research and development, showcasing both its enduring principles and its adaptation to changing times [1][4][9]. Group 1: Consistency in Leadership and Culture - The core participants in the symposium have remained consistent over the years, highlighting the importance of research personnel in the company's strategic discussions [3]. - The management's focus on "listening" to researchers has been a constant theme, emphasizing respect for scientific inquiry and the importance of feedback in the R&D process [4][6]. Group 2: Evolution of Research Focus - The topics discussed at the symposium have evolved significantly over the past three years, reflecting changes in the pharmaceutical industry and the company's strategic priorities [5][9]. - In 2024, the focus was on "breakthrough" and "foundation," with the company celebrating the achievement of 25 production approvals and 18 new product launches [6]. - By 2025, the emphasis shifted to "speed" and "collaboration," as the company secured 36 registration approvals and aimed for faster product development and cross-departmental cooperation [6][8]. - In 2026, discussions centered around "AI technology empowerment," "innovation," and "R&D," indicating a shift towards more advanced and integrated approaches in research [6][8]. Group 3: Strategic Directions for 2026 - The company plans to accelerate its R&D efforts towards high-value areas, focusing on innovative drugs and high-barrier sectors to secure future growth [8]. - There is a strong emphasis on creating a synergistic ecosystem between R&D, production, and market needs, aiming for efficient conversion of research outcomes into marketable products [8]. - The management aims to foster a self-driven research culture by enhancing career development pathways and creating an environment that values innovation and tolerates failure [8][10].